Vitamin A Supplementation Improves Retinal Function in Infants at Risk of Retinopathy of Prematurity

Mactier, Helen; McCulloch, Daphne L.; Hamilton, Ruth; Galloway, Peter; Bradnam, Michael S.; Young, David; Lavy, Timothy; Farrell, Lesley; Weaver, Lawrence T.

doi:10.1016/j.jpeds.2011.12.013

Cited by 51 publications

(31 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…33,34 These findings are comparable to those reported by others. 2,17,21,22 Our infants showed no signs of renal failure but low glomerular filtration related to their degree of prematurity were reported in the literature, 12,13 which may partly explain the high retinyl palmitate concentrations. high-dose i.m.…”

Section: Discussionsupporting

confidence: 62%

Characterization of the vitamin A transport in preterm infants after repeated high-dose vitamin A injections

et al. 2014

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 62%

Characterization of the vitamin A transport in preterm infants after repeated high-dose vitamin A injections

et al. 2014

View full text Add to dashboard Cite

show abstract

“…Recent meta-analysis showed that supplementing very low birthweight infants with vitamin A reduces oxygen use at 1 month of age [26]. Supplementation with vitamin A may also improve retinal function in infants at risk of retinopathy of prematurity [27]. Preterm infants are prone to vitamin A deficiency due to low stores of vitamin A at birth, low intake and poor enteral absorption.…”

Section: Resultsmentioning

confidence: 99%

All-Trans-Retinoic Acid Attenuates Intestinal Injury in a Neonatal Rat Model of Necrotizing Enterocolitis

et al. 2013

View full text Add to dashboard Cite

Background: Ischemia/reperfusion-induced intestinal injury is mediated by reactive oxygen species and inflammatory mediators. Objectives: This study was designed to evaluate whether all-trans-retinoic acid (ATRA) administration can attenuate intestinal injury and to analyze the antioxidant and anti-inflammatory effects of ATRA in a neonatal rat model of necrotizing enterocolitis (NEC). Methods: Twenty-nine Wistar albino rat pups were randomly divided into 3 groups: group 1 = control, group 2 = NEC and saline, and group 3 = NEC and ATRA treatment. NEC was induced by hyperosmolar enteral formula feeding and exposure to hypoxia after cold stress at +4°C and oxygen. Pups in group 3 were injected intraperitoneally with ATRA (0.5 mg/kg body weight) once a day prior to each NEC procedure, beginning on postnatal day 1 and daily through postnatal day 4. The pups were killed on the 4th day and their intestinal tissues were harvested for biochemical and histopathological analysis. Results: Mucosal injury scores and intestinal malondialdehyde levels in group 2 were found to be significantly higher than other groups (p < 0.05). Intestinal superoxide dismutase and glutathione peroxidase activities in group 3 were significantly higher than group 2 (p = 0.04 and p = 0.04, respectively). Intestinal tissue tumor necrosis factor-α levels were significantly reduced with ATRA treatment in group 3 compared to group 2 (p < 0.001). Conclusions: It is likely that oxidative stress and inflammatory mediators contributed to the pathogenesis of NEC and that ATRA had a protective effect on intestinal injury through its anti-inflammatory and antioxidant properties.

show abstract

“…Vitamin A supplementation reduces infant mortality (67). Retinal vitamin A allows adequate rhodopsin availability for phototransduction and protects the photoreceptors from the harmful effects of hypoxia and hyperoxia (68). Studies show a trend for decreased incidence of threshold ROP in ELBW infants treated with 10,000 IU intramuscular vitamin A three times a week (0%) compared with 16% in those who received half this dose (69).…”

Section: Pharmacologic Interventions In Ropmentioning

confidence: 99%

“…Studies show a trend for decreased incidence of threshold ROP in ELBW infants treated with 10,000 IU intramuscular vitamin A three times a week (0%) compared with 16% in those who received half this dose (69). A recent double-blind, randomized controlled trial of early high-dose intramuscular vitamin A supplementation for infants at risk of ROP showed improves retinal function at 36 weeks' PMA (68). A meta-analysis of the three studies suggests a trend towards reduced incidence of ROP in vitamin A supplemented infants (70).…”

Section: Pharmacologic Interventions In Ropmentioning

confidence: 99%

Pharmacologic interventions for the prevention and treatment of retinopathy of prematurity

Beharry

Valencia

Lazzaro

et al. 2016

Seminars in Perinatology

View full text Add to dashboard Cite

Retinopathy of prematurity (ROP), a significant morbidity in prematurely born infants, is the most common cause of visual impairment and blindness in children and persists till adulthood. Strict control of oxygen therapy and prevention of intermittent hypoxia are key in the prevention of ROP, but pharmacologic interventions have decreased risk of ROP. Various drug classes such as methylxanthines (caffeine), VEGF inhibitors, anti-oxidants, and others have decreased ROP occurrence. The timing of pharmacologic intervention remains unsettled, but early prevention rather than controlling disease progression may be preferred. These drugs act through different mechanisms and synergistic approaches should be considered to maximize efficacy and safety.

show abstract

Vitamin A Supplementation Improves Retinal Function in Infants at Risk of Retinopathy of Prematurity

Cited by 51 publications

References 24 publications

Characterization of the vitamin A transport in preterm infants after repeated high-dose vitamin A injections

Characterization of the vitamin A transport in preterm infants after repeated high-dose vitamin A injections

All-Trans-Retinoic Acid Attenuates Intestinal Injury in a Neonatal Rat Model of Necrotizing Enterocolitis

Pharmacologic interventions for the prevention and treatment of retinopathy of prematurity

Contact Info

Product

Resources

About